Amazon cover image
Image from Amazon.com

Nanotherapeutics for the Treatment of Hepatocellular Carcinoma

By: Material type: TextTextPublication details: Singapore : Bentham Science Publishers, (c)2022.Description: 1 online resource (557 pages)Content type:
  • text
Media type:
  • computer
Carrier type:
  • online resource
ISBN:
  • 9789815039740
  • 9815039741
Subject(s): Genre/Form: LOC classification:
  • RC280 .N366 2022
Online resources: Available additional physical forms:
Contents:
Title -- Copyright -- End User License Agreement -- Contents -- Preface -- List of Contributors -- Hepatocellular Carcinoma: Diagnosis, Molecular Pathogenesis, Biomarkers, and Conventional Therapy -- Biswajit Mukherjee*, 1, Manasadeepa Rajagopalan2, Samrat Chakraborty1, Prasanta Ghosh1, Manisheeta Ray1, Ramkrishna Sen1 and Iman Ehsan1 -- INTRODUCTION -- CANCER AND ITS TYPES -- Primary Liver Cancer -- Hepatocellular Carcinoma (HCC) -- Intrahepatic Cholangiocarcinoma (Bile Duct Cancer) -- Angiosarcoma and Hemangiosarcoma -- Hepatoblastoma -- Secondary Liver Cancer
Anatomical Resection -- Laparoscopic Resection of The Liver -- Surgical Resection of Re-Occurring HCC -- Liver Transplantation -- Ablation -- Palliative Treatment -- Embolizing Therapies for HCC -- Transarterial Chemoembolization (TACE) -- Radiotherapy -- Systemic Therapies of HCC -- First-line Therapy -- Second-line Therapy -- Multi-Target Tyrosine Kinase Inhibitors -- Immune Checkpoint Inhibitor -- FUTURE PERSPECTIVES -- CONCLUSIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES
Subject: Hepatocellular carcinoma (HCC) is a leading cause of death globally. Conventional chemotherapeutic agents are unable to penetrate cancerous hepatocytes completely and are toxic to non cancerous cells and tissues. This toxicity significantly compromises the therapeutic outcome of conventional chemotherapeutic agents which is also reflected in the high mortality of the disease. Nanotherapeutics have shed new light onto HCC treatment by enabling site-specific in vivo delivery of chemotherapeutics specifically to neoplastic hepatocytes without affecting normal hepatocytes. Thus, nanotherapeutics h.
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Collection Call number URL Status Date due Barcode
Online Book (LOGIN USING YOUR MY CIU LOGIN AND PASSWORD) Online Book (LOGIN USING YOUR MY CIU LOGIN AND PASSWORD) G. Allen Fleece Library ONLINE Non-fiction RC280.5 (Browse shelf(Opens below)) Link to resource Available on1314619846

Description based upon print version of record.

Includes bibliographies and index.

Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Preface -- List of Contributors -- Hepatocellular Carcinoma: Diagnosis, Molecular Pathogenesis, Biomarkers, and Conventional Therapy -- Biswajit Mukherjee*, 1, Manasadeepa Rajagopalan2, Samrat Chakraborty1, Prasanta Ghosh1, Manisheeta Ray1, Ramkrishna Sen1 and Iman Ehsan1 -- INTRODUCTION -- CANCER AND ITS TYPES -- Primary Liver Cancer -- Hepatocellular Carcinoma (HCC) -- Intrahepatic Cholangiocarcinoma (Bile Duct Cancer) -- Angiosarcoma and Hemangiosarcoma -- Hepatoblastoma -- Secondary Liver Cancer

Surgical Resection in Advanced HCC -- Anatomical Resection -- Laparoscopic Resection of The Liver -- Surgical Resection of Re-Occurring HCC -- Liver Transplantation -- Ablation -- Palliative Treatment -- Embolizing Therapies for HCC -- Transarterial Chemoembolization (TACE) -- Radiotherapy -- Systemic Therapies of HCC -- First-line Therapy -- Second-line Therapy -- Multi-Target Tyrosine Kinase Inhibitors -- Immune Checkpoint Inhibitor -- FUTURE PERSPECTIVES -- CONCLUSIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES

Hepatocellular Carcinoma and Therapeutic Challenges.

Hepatocellular carcinoma (HCC) is a leading cause of death globally. Conventional chemotherapeutic agents are unable to penetrate cancerous hepatocytes completely and are toxic to non cancerous cells and tissues. This toxicity significantly compromises the therapeutic outcome of conventional chemotherapeutic agents which is also reflected in the high mortality of the disease. Nanotherapeutics have shed new light onto HCC treatment by enabling site-specific in vivo delivery of chemotherapeutics specifically to neoplastic hepatocytes without affecting normal hepatocytes. Thus, nanotherapeutics h.

COPYRIGHT NOT covered - Click this link to request copyright permission:

https://lib.ciu.edu/copyright-request-form

There are no comments on this title.

to post a comment.